{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6"},{"groupId":"OG001","value":"78.2"}]}],"title":"Dysphagia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6"},{"groupId":"OG001","value":"78.2"}]}],"title":"Dietary Restrictions"},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6"},{"groupId":"OG001","value":"78.2"}]}],"title":"Pain QS22"},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6"},{"groupId":"OG001","value":"78.2"}]}],"title":"Reflux"},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6"},{"groupId":"OG001","value":"78.2"}]}],"title":"Anxiety"},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.4"},{"groupId":"OG001","value":"78.2"}]}],"title":"Dry Mouth"},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.8"},{"groupId":"OG001","value":"78.2"}]}],"title":"Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6"},{"groupId":"OG001","value":"78.2"}]}],"title":"Hair Loss"},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6"},{"groupId":"OG001","value":"78.2"}]}],"title":"Taste Problems"}],"denoms":[{"counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"170"}],"units":"Participants"}],"description":"The Quality of Life Questionnaire Stomach Cancer Module 22 (QLQ-STO22) assessed symptoms and treatment-related side effects commonly reported in participants. There are 22 questions which comprise 5 scales (dysphagia, dietary restrictions, pain QS22, reflux, and anxiety) and 4 single items (dry mouth, hair loss, taste problems, body image). Most questions use 4-point scale (1='Not at all', 2=a little, 3=quite a bit and 4='Very much'). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100, where higher score=better level of functioning or greater degree of symptoms.","groups":[{"description":"Participants received 35 mg/m\\^2 of TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until a discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.","id":"OG000","title":"TAS-102+BSC"},{"description":"Participants received 35 mg/m\\^2 of matching placebo for TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.","id":"OG001","title":"Placebo+BSC"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on the ITT population that included all randomized participants, regardless of whether or not study treatment was administered.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 1 Day 1 up to end of treatment (EOT) (within 30 days of last study treatment) (maximum duration: up to approximately 46 months)","title":"EORTC Quality of Life Questionnaire - Gastric-specific Module (EORTC QLQ-STO22): Percentage of Participants With Overall Compliance","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}